Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Inspire Medical Systems (NYSE:INSP – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings.
Profitability
This table compares Lucid Diagnostics and Inspire Medical Systems’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Lucid Diagnostics | -2,169.07% | -901.79% | -121.11% |
Inspire Medical Systems | -3.39% | -3.93% | -3.38% |
Analyst Recommendations
This is a summary of current recommendations for Lucid Diagnostics and Inspire Medical Systems, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Lucid Diagnostics | 0 | 0 | 2 | 0 | 3.00 |
Inspire Medical Systems | 0 | 4 | 10 | 0 | 2.71 |
Insider & Institutional Ownership
74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are held by institutional investors. 4.8% of Lucid Diagnostics shares are held by insiders. Comparatively, 4.1% of Inspire Medical Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Lucid Diagnostics and Inspire Medical Systems’ gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Lucid Diagnostics | $2.43 million | 19.05 | -$52.67 million | ($1.27) | -0.73 |
Inspire Medical Systems | $624.80 million | 12.11 | -$21.15 million | ($0.74) | -337.49 |
Inspire Medical Systems has higher revenue and earnings than Lucid Diagnostics. Inspire Medical Systems is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Lucid Diagnostics has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.
Summary
Inspire Medical Systems beats Lucid Diagnostics on 8 of the 14 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Inspire Medical Systems
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.